RESEARCHER PROFILE

Satoshi Ikeda

← Back to Kansai Medical University

S

Kansai Medical University

Lung Cancer Diagnosis and TreatmentLung Cancer Treatments and MutationsInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisCancer Immunotherapy and BiomarkersLung Cancer Research Studies

Satoshi Ikeda works in Lung Cancer Diagnosis and Treatment, Lung Cancer Treatments and Mutations, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies. Recorded institutional associations include Kansai Medical University, Kumamoto University Hospital, Kanagawa Cardiovascular and Respiratory Center.

371Publications
3,670Citations
29H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

    2019 · 603 citations
  2. In situ localization of Propionibacterium acnes DNA in lymph nodes from sarcoidosis patients by signal amplification with catalysed reporter deposition

    2002 · 107 citations
  3. Trabecular Bone Turnover and Bone Marrow Cell Development in Tail-Suspended Mice

    1999 · 100 citations
  4. A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis

    2020 · 95 citations
  5. Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR

    2022 · 93 citations
  6. Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial

    2022 · 85 citations
  7. A Comparison of Alfacalcidol and Menatetrenone for the Treatment of Bone Loss in an Ovariectomized Rat Model of Osteoporosis

    2002 · 74 citations
  8. Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease

    2017 · 70 citations
  9. Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L

    2021 · 70 citations
  10. Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status

    2017 · 65 citations
  11. Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study

    2016 · 57 citations
  12. Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?

    2015 · 52 citations
  13. Pulmonary granulomas caused experimentally in mice by a recombinant trigger-factor protein of Propionibacterium acnes.

    2003 · 51 citations
  14. Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study

    2015 · 50 citations
  15. Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia

    2019 · 50 citations
  16. Intermittent Administration of Human Parathyroid Hormone(1–34) Prevents Immobilization-Related Bone Loss by Regulating Bone Marrow Capacity for Bone Cells in ddY Mice

    1999 · 49 citations
  17. A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC

    2021 · 49 citations
  18. Detection of gene point mutation in paraffin sections using in situ loop‐mediated isothermal amplification

    2007 · 47 citations
  19. Predictive Factors for the Long-Term Deterioration of Pulmonary Function in Interstitial Lung Disease Associated with Anti-Aminoacyl-tRNA Synthetase Antibodies

    2018 · 47 citations
  20. Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis

    2017 · 44 citations
  21. A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903

    2021 · 43 citations
  22. Effects of atrial natriuretic peptide on inter-organ crosstalk among the kidney, lung, and heart in a rat model of renal ischemia-reperfusion injury

    2014 · 36 citations
  23. Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases

    2020 · 36 citations
  24. Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer

    2023 · 36 citations
  25. Serial changes in negative T wave on electrocardiogram in acute pulmonary thromboembolism

    1999 · 34 citations

← Return to the university profile